BNB Plus Corp. Appoints Three New Directors Identified Through Ongoing Strategic Review

BNB Plus Corp. appointed three new directors — Richard Shorten as Chairman, Lok Lee and Todd Larsen — identified through the company's ongoing strategic review process. The incoming members replace Robert Catell, Joseph Ceccolli and Yacov Shamash, while James Haft and Judith Murrah continue in their current board roles. The new directors bring corporate restructuring, institutional finance and digital-asset infrastructure experience aligned with the company's BNB treasury strategy, which it operates alongside its LineaRx biotech subsidiary (formerly Applied DNA Sciences).

•1mo ago

BNB Plus Corp. (BNBX) Secures Initial Commitments for $4.1M in Strategic Financing

BNB Plus Corp. secured $4.1 million in initial commitments for a $5 million convertible preferred stock financing, led by Silvermine Capital and GlobalStake. The Series B-1 shares are priced at $1.05, representing a 176% premium to the common stock's May 22 close, while Series B-2 shares for existing investors are priced at $0.38. Proceeds will bolster the company's digital asset treasury and fund a strategic review of its business, including potential monetization of its biotech subsidiary LineaRx.

•4mo ago